Pfizer Inc. $PFE Position Cut by Moody National Bank Trust Division

Moody National Bank Trust Division lessened its position in Pfizer Inc. (NYSE:PFE) by 20.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 82,052 shares of the biopharmaceutical company’s stock after selling 21,093 shares during the period. Moody National Bank Trust Division’s holdings in Pfizer were worth $2,043,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank increased its holdings in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at $311,000. Finally, Waterloo Capital L.P. boosted its stake in shares of Pfizer by 16.6% during the 2nd quarter. Waterloo Capital L.P. now owns 17,541 shares of the biopharmaceutical company’s stock worth $425,000 after acquiring an additional 2,499 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.8%

NYSE PFE opened at $26.98 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The stock has a market cap of $153.39 billion, a PE ratio of 19.83 and a beta of 0.47. The firm has a 50-day simple moving average of $26.75 and a 200 day simple moving average of $25.64. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade: Guggenheim raised its price target to $36 and reiterated a Buy, signaling sizable upside vs. current levels and supporting bullish investor sentiment. Article Title
• Positive Sentiment: Lyme vaccine efficacy: Pfizer and Valneva reported >70% efficacy in the Phase 3 VALOR trial — the result bolsters Pfizer’s vaccine pipeline and longer‑term revenue optionality if regulators approve the shot. Article Title
• Positive Sentiment: Oncology progress highlighted by management: CFO Dave Denton discussed recent oncology milestones on NYSE Live, reinforcing the narrative that new oncology assets could drive growth beyond legacy franchises. Article Title
• Positive Sentiment: Bullish research/coverage: Several outlets and analysts (Seeking Alpha, 247wallst, The Motley Fool coverage) are calling a turnaround and higher targets for PFE based on pipeline momentum and valuation, which supports buying interest. Article Title
• Neutral Sentiment: Investor events: Pfizer scheduled a May 5 webcast to discuss Q1 results and a first‑quarter performance report — gives investors a formal update and a clear date to reassess fundamentals. Article Title
• Negative Sentiment: Trial missed primary endpoint: Although efficacy was strong, the VALOR trial failed to meet its prespecified primary statistical endpoint because fewer participants contracted Lyme disease than expected — this raises regulatory and labeling uncertainty that can delay or complicate approval. Article Title
• Negative Sentiment: Partner Valneva’s selloff: Valneva shares plunged after the announcement despite the efficacy readout, highlighting market concern about regulatory risk and commercial prospects; negative headlines around the partner can create near‑term volatility for Pfizer. Article Title

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday. BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Finally, UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.